Literature DB >> 10578632

A clinical and histopathological study of macular type of post-kala-azar dermal leishmaniasis.

V Ramesh1, N Singh.   

Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is an uncommon sequel seen in patients with a previous attack of kala-azar (KA). It is characterized by hypopigmented macules and erythematous eruptions leading to the formation of papules, plaques and nodules. Little attention has been paid to the rare group of patients who present with only hypopigmented macules. The present study has described the distribution of lesions in macular PKDL and their histopathology.

Entities:  

Mesh:

Year:  1999        PMID: 10578632     DOI: 10.1177/004947559902900406

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  4 in total

1.  Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis.

Authors:  P Salotra; G Sreenivas; G P Pogue; N Lee; H L Nakhasi; V Ramesh; N S Negi
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.

Authors:  Samiran Saha; Tuhina Mazumdar; Khairul Anam; Rajesh Ravindran; Bibhas Bairagi; Bibhuti Saha; Ramapada Goswami; Netai Pramanik; Subhashis K Guha; Sourjya Kar; Dwijadas Banerjee; Nahid Ali
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

3.  Histopathology of Post Kala-azar Dermal Leishmaniasis.

Authors:  V Ramesh; M Ramam
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

4.  Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012.

Authors:  Philippe Desjeux; Raj Shankar Ghosh; Pritu Dhalaria; Nathalie Strub-Wourgaft; Ed E Zijlstra
Journal:  Parasit Vectors       Date:  2013-07-02       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.